• View the Talks
• 41 min
  1. The clinical syndrome of Alzheimer's disease

  • Dr. Jonathan Schott
• 21 min
  2. Lewy body dementia

  • Prof. John-Paul Taylor
• 43 min
  3. Pathology of Alzheimer's disease

  • Prof. Tamas Revesz
• 36 min
  4. Genetics of early onset Alzheimer's disease

  • Prof. Ekaterina Rogaeva
• 32 min
  5. Thirty years of Alzheimer's genetics: what's new and what's next?

  • Dr. Lars Bertram
• 40 min
  6. Immunotherapy as an approach to treating Alzheimer's disease

  • Prof. David Morgan
• 19 min
  7. Pathogenic mechanisms and therapeutic approaches for the tauopathies

  • Prof. Karen Duff
• 36 min
  8. Vascular factors in Alzheimer's disease

  • Dr. Deborah Gustafson
• 41 min
  9. Neuroimaging markers in AD trials

  • Prof. Nick Fox
• 70 min
  10. Imaging amyloid: now that we can see it, what does it all mean?

  • Prof. William Klunk
• 51 min
  11. Metabolic and biochemical alterations in Alzheimer's disease: facts and fictions

  • Prof. Mark A. Smith
• 54 min
  12. Abeta toxicity 1

  • Prof. Colin L. Masters
• 28 min
  13. Abeta toxicity 2

  • Prof. Colin L. Masters
• 43 min
  14. Alzheimer's disease: where are we up to?

  • Prof. John Hardy
• 53 min
  15. ApoE4 - the most prevalent genetic risk factor for Alzheimer's disease

  • Prof. Daniel Michaelson
• Archived Lectures *These may not cover the latest advances in the field
• 29 min
  16. Lewy body dementia

  • Prof. Ian McKeith

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Differential diagnosis of dementia (1)
3. LB dementia in the literature
4. Dementia with Lewy bodies
5. Differential diagnosis of dementia (2)
6. Manifestations of LB disease
7. Laboratory detection of Lewy body disease
8. Terminology review
9. Diagnostic criteria for DLB (1)
10. Neuropathological features of DLB
11. LB reflection in dementia
12. Alpha-synuclein oligomer levels increased in LBD
13. Imaging amyloid deposition in LBD
14. Diagnostic criteria for DLB (2)
15. Neuropsychological testing in AD vs. DLB
16. Visuo-perceptual dysfunction in LBD
17. Blood flow SPECT images
18. Assessing cognitive fluctuation in DLB
19. Parkinsonism in DLB: key facts
20. Neuroleptic sensitivity in DLB
21. SPECT FP-CIT as a diagnostic test for DLB
22. Current management of DLB
23. Cholinesteraze inhibitors in DLB
24. Cholinergic activities in post-mortem brain
25. NPI scores in a trial of rivastigmine in DLB
26. COGDRAS speed of attention
27. Why is DLB important? (1)
28. Why is DLB important? (2)

Topics Covered

• Dementia with Lewy bodies (DLB)
• Parkinson's disease dementia (PDD)
• Clinical and pathological diagnosis
• Cerebral spinal fluid (CSF) and imaging biomarkers
• Clinical progression
• Treatment options

Links

Series:

• Alzheimer's Disease

Categories:

• Clinical Practice
• Neuroscience

Therapeutic Areas:

• Neurology

Talk Citation

Publication History

• Published on August 26, 2010

Financial Disclosures

• Prof. Ian McKeith, Speaker's Bureau: GE Healthcare, Novartis